1
|
Elterman D, Alshak MN, Martinez Diaz S, Shore N, Gittleman M, Motola J, Pike S, Hermann C, Terens W, Kohan A, Gonzalez R, Katz A, Schiff J, Goldfischer E, Grunberger I, Tu L, Kaminetsky J, Chughtai B. An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device. J Endourol 2022; 37:74-79. [PMID: 36070450 PMCID: PMC9810348 DOI: 10.1089/end.2022.0226] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Purpose: To document the effect of the temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Israel) on sexual function from a multicenter, randomized, single-blinded, sham-controlled trial. Materials and Methods: Men were randomized 2:1 between iTind and sham procedure arms. The iTind was placed for 5-7 days and an 18F Foley catheter was inserted and removed for the iTind and sham group, respectively. Patients were assessed at baseline, 3, and 12 months postoperatively using the Sexual Health Inventory for Men (SHIM) and International Index of Erectile Function (IIEF). Unblinding occurred at 3 months. Results: We studied 185 men with a mean age of 61.1 ± 6.5 years. There was no difference in SHIM or total IIEF between iTind and sham at 3 months or in the iTind arm at 12 months compared with baseline. Men in the iTind arm without erectile dysfunction at baseline showed an improvement in total IIEF score of +6.07 ± 21.17 points (p = 0.034) at 12 months, in addition to an improvement in ejaculatory function. SHIM scores remained unchanged in all groups, regardless of age, prostate volume, or baseline erectile function. Conclusion: No changes were observed in sexual and ejaculatory function of patients with iTind regardless of a man's age, prostate volume, and baseline sexual function. Clinicaltrials.gov: NCT02506465.
Collapse
Affiliation(s)
- Dean Elterman
- Division of Urology, University Health Network, University of Toronto, Toronto, Canada
| | - Mark N. Alshak
- Department of Urology, Weill Cornell Medicine, New York, New York, USA
| | | | - Neal Shore
- Department of Urology, Carolina Urology Research Center, Myrtle Beach, South Carolina, USA
| | - Marc Gittleman
- Department of Urology, South Florida Medical Research, Miami, Florida, USA
| | - Jay Motola
- Department of Urology, Mt Sinai Hospital, New York, New York, USA
| | - Sheldon Pike
- Department of Urology, St John's Episcopal, New York, New York, USA
| | - Craig Hermann
- Department of Urology, Clinical Research Center of Florida, Miami, Florida, USA
| | - William Terens
- Department of Urology, Premier Urology Group, Edison, New Jersey, USA
| | - Alfred Kohan
- Department of Urology, Integrated Medical Professionals, Long Island, New York, USA
| | - Ricardo Gonzalez
- Department of Urology, Houston Metro Urology, Houston, Texas, USA
| | - Aaron Katz
- Department of Urology, NYU Winthrop Hospital, Long Island, New York, USA
| | - Jeffrey Schiff
- Department of Urology, NYU Winthrop Hospital, Long Island, New York, USA
| | - Evan Goldfischer
- Department of Urology, Premier Medical Group of the Hudson Valley, Poughkeepsie, New York, USA
| | - Ivan Grunberger
- Department of Urology, New York Methodist Hospital, Brooklyn, New York, USA
| | - Le Tu
- Department of Urology, Sherbrooke University Hospital, Sherbrooke, Canada
| | - Jed Kaminetsky
- Department of Urology, Manhattan Medical Research, Manhattan, New York, USA
| | - Bilal Chughtai
- Department of Urology, Weill Cornell Medicine, New York, New York, USA.,Address correspondence to: Bilal Chughtai, MD, Department of Urology, Weill Cornell Medicine, 425 East 61st Street, 12th Floor, New York, NY 10065, USA
| |
Collapse
|